Evidence map›Paper›PMID 28959492›Full record

Trial reportStroke and vascular neurology2017

Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial.

Lily Song, Xia Wang, Thompson Robinson, Richard I Lindley, Hisatomi Arima, Pablo M Lavados, Xiaoying Chen, John Chalmers, Craig S Anderson

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stroke and vascular neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lily SongThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.
Xia WangThe George Institute for Global Health, The University of New South Wales, Sydney, Australia.
Thompson RobinsonDepartment of Cardiovascular Sciences and NIHR Biomedical Research Unit for Cardiovascular Sciences, University of Leicester, Leicester, UK.
Richard I LindleyThe George Institute for Global Health, The University of New South Wales, Sydney, Australia.
Hisatomi ArimaThe George Institute for Global Health, The University of New South Wales, Sydney, Australia.
Pablo M LavadosClínica Alemana de Santiago, Universidad del Desarrollo, Concepción, Chile.
Xiaoying ChenThe George Institute for Global Health, The University of New South Wales, Sydney, Australia.
John ChalmersThe George Institute for Global Health, The University of New South Wales, Sydney, Australia.
Craig S AndersonThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe characteristics of patients with acute ischaemic stroke (AIS) and their management vary across regions, which may influence outcomes. We examined for differential patterns of outcome between China and non-China participants of the ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED), which tested different alteplase doses in AIS.

methodsENCHANTED was an international, multicentre, open, blinded-endpoint trial of the effects of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase on 90-day disability outcomes and symptomatic intracerebral haemorrhage (sICH) in 3310 patients with AIS.

resultsParticipants (n=1419, 48%) in China were younger, and more often male, hypertensive and with prior stroke and coronary artery disease, but less likely to have atrial fibrillation and use antihypertensive, antithrombotic and lipid-lowering agents, compared with non-China patients with AIS. Although China participants had more AIS due to large artery occlusion, were treated later and had differing ancillary management, there was no significant difference in 90-day modified Rankin scale scores 2-6 (55.6% vs 47.8%; OR, adjusted for baseline and management factors 0.87 (95% CI 0.71 to 1.07; p=0.20)) and risk of sICH (Safe Implementation of Thrombolysis in Stroke-Monitoring Study criteria: 1.4% vs 1.8%; p=0.12) compared with non-China participants. There was no heterogeneity in the treatment effects of low-dose versus standard-dose alteplase between China and non-China participants.

conclusionPatients with AIS recruited to the ENCHANTED trial in China had similar outcomes in response to thrombolysis treatment despite significantly differing demographic, clinical and management factors to patients with AIS in other regions.

Indexed as

Thrombolytic TherapyAgedAged, 80 and overCerebral HemorrhageChinaDisability EvaluationFemaleFibrinolytic AgentsHumansInfusions, IntravenousIschemic StrokeMaleMiddle AgedProspective StudiesRecovery of FunctionRisk FactorsFibrinolytic AgentsTissue Plasminogen Activatoracute ischemic strokeclinical trialintravenous thrombolysis

Identifiers

PMID28959492
PMCPMC5600017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.